Literature DB >> 9056162

Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.

A Monegal1, M Navasa, N Guañabens, P Peris, F Pons, M J Martinez de Osaba, A Rimola, J Rodés, J Muñoz-Gómez.   

Abstract

The purpose of this study was to determine the prevalence of osteoporosis, to estimate the bone turnover and hormonal status, and to identify the factors associated with bone disease in patients with end-stage liver disease who were referred for orthotopic liver transplantation. A prospective study was performed on 58 cirrhotic patients (6 with primary biliary cirrhosis, 14 with alcoholic cirrhosis, and 38 with posthepatitic cirrhosis), who were referred for orthotopic liver transplantation. Patients, excluding those with primary biliary cirrhosis, were classified in Child-Pugh groups according to the severity of liver disease (class B [28 patients], class C [24 patients]). Biochemical parameters of bone mineral metabolism and standard liver function tests were measured in all patients. Additionally, serum osteocalcin, urinary hydroxyproline/creatinine ratio, serum intact parathyroid hormone, serum 25-hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, follicle-stimulating hormone, and luteinizing hormone levels were determined in patients and controls within the same age range. Plasma testosterone, sex hormone-binding globulin levels, and free testosterone index were obtained for all men included in the study. Bone mass of the lumbar spine and femur were measured by dual X-ray absorptiometry (DPX-L), and were expressed as a standard deviation of mean values (Z-score) from a sex and age-matched control group. Spinal X-rays were obtained to assess vertebral fractures. Osteoporosis was considered as a factor in spinal bone mineral density with a Z-score below 2 or at least one vertebral fracture. Twenty-five patients (43%) had osteoporosis, with lower bone mass measurements in the lumbar spine than in the femoral neck (P < 0.005). Alcoholic and Child-Pugh C patients showed the lowest femoral bone mineral density values. Cirrhotic patients showed lower osteocalcin levels than controls (14.3 +/- 5.9 vs. 18.2 +/- 8.1 ng/ml; P < 0.05) and showed increased urinary hydroxyproline (125.1 +/- 51.5 vs. 107.9 +/- 26.6 nM/mg creatinine; P < 0.05). Serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone levels were significantly lower in cirrhotic patients than in controls (10.3 +/- 9.1 vs. 23.1 +/- 26.6 ng/ml; P = 0.000), (12.9 +/- 9.1 vs. 48.3 +/- 11.5 pg/ml; P = 0.000), (16.6 +/- 9.2 vs. 27.9 +/- 8.2 pg/ml; P = 0.000), with no differences between Child-Pugh groups. Alcoholic Child-Pugh C patients showed the lowest 25-hydroxyvitamin D serum values (4.5 +/- 2.2 ng/ml; P < 0.05). Male patients had lower testosterone levels than controls (302.5 +/- 229.4 vs. 556.7 +/- 146.5 ng/dl; P = 0.000), with increased sex hormone-binding globulin values. Levels of testosterone and gonadotropin were related to Child-Pugh classification. No correlation was found between bone mass and hormonal values. A significant decrease in bone mass, particularly in the lumbar spine, is seen in end-stage cirrhotic patients. Reduced bone formation and significant disorders of bone mineral metabolism, such as vitamin D deficiency, reduced parathyroid hormone levels, and hypogonadism are involved. Moreover, severity and etiology of the liver disease are the main risk factors for developing bone loss and mineral metabolism disorders in patients referred for orthotopic liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056162     DOI: 10.1007/s002239900205

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  47 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Osteoporosis in chronic liver disease.

Authors:  J Heathcote
Journal:  Curr Gastroenterol Rep       Date:  1999-12

3.  Pamidronate and osteoporosis prevention in liver transplant recipients.

Authors:  Pietra Pennisi; Andrea Trombetti; Emiliano Giostra; Gilles Mentha; René Rizzoli; Carmelo E Fiore
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

4.  Bone disorders in experimentally induced liver disease in growing rats.

Authors:  Viktória Ferencz; Csaba Horváth; Béla Kári; János Gaál; Szilvia Mészáros; Zsuzsanna Wolf; Dalma Hegedus; Andrea Horváth; Anikó Folhoffer; Ferenc Szalay
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

5.  Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.

Authors:  D J McConn; Y S Lin; T L Mathisen; D K Blough; Y Xu; T Hashizume; S L Taylor; K E Thummel; M C Shuhart
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

6.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 7.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 8.  Male hypogonadism in cirrhosis and after liver transplantation.

Authors:  C Foresta; M Schipilliti; F A Ciarleglio; A Lenzi; D D'Amico
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

Review 9.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

10.  Prevalence of vitamin D deficiency in chronic liver disease.

Authors:  J Arteh; S Narra; S Nair
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.